Literature DB >> 28689877

A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate.

Vania Giacomet1, Katia Maruca2, Alessandro Ambrosi3, Gian Vincenzo Zuccotti4, Stefano Mora5.   

Abstract

BACKGROUND: The use of tenofovir disoproxil fumarate (TDF) has simplified the antiretroviral regimen for HIV-infected patients and improved their compliance with treatment, but it has been associated with decreased bone mineral density (BMD) in adult patients, and data in pediatric patients are debated. The aim of the current study was to assess the long-term effect of TDF on BMD in young patients.
METHODS: BMD was measured at the lumbar spine and in the whole skeleton in 26 HIV-infected youths (13 female and 13 male, aged 5 to 17 years at baseline). BMD was measured yearly for 10 years as part of standard care. BMD changes were compared with those calculated from 202 healthy subjects aged 3 to 24 years.
FINDINGS: All patients had good control of the infection during the 10-year study. BMD measurements changed significantly (P <0 ⋅ 0001) in HIV-infected youths. The mean annual BMD increment at the lumbar spine was 0 ⋅ 046 (0 ⋅ 006) g/cm2 and 0 ⋅ 042 (0 ⋅ 006) g/cm2 in males and females, respectively. The differences between the slopes of patients and healthy controls were not significant. The annual BMD increment of the whole skeleton was 0 ⋅ 030 (0 ⋅ 005) g/cm2 in males and 0 ⋅ 019 (0 ⋅ 004) g/cm2 in females. The slopes of BMD changes of patients and healthy controls did not differ significantly.
INTERPRETATION: These data indicate that treatment with a TDF-containing antiretroviral regimen does not impair BMD in young patients with HIV-infection. Larger studies are needed to confirm these results.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Adolescents; Bone mineral density; Children; Tenofovir disoproxil fumarate

Mesh:

Substances:

Year:  2017        PMID: 28689877     DOI: 10.1016/j.ijantimicag.2017.03.026

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

Review 1.  Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings.

Authors:  Steve Innes; Kunjal Patel
Journal:  Curr Opin HIV AIDS       Date:  2018-05       Impact factor: 4.283

2.  Older age at initiation of antiretroviral therapy predicts low bone mineral density in children with perinatally-infected HIV in Zimbabwe.

Authors:  Celia L Gregson; April Hartley; Edith Majonga; Grace McHugh; Nicola Crabtree; Ruramayi Rukuni; Tsitsi Bandason; Cynthia Mukwasi-Kahari; Kate A Ward; Hilda Mujuru; Rashida A Ferrand
Journal:  Bone       Date:  2019-05-10       Impact factor: 4.398

3.  Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate.

Authors:  Kate Braithwaite; Tristan D McPherson; Yanhan Shen; Stephen Arpadi; Stephanie Shiau; Gillian Sorour; Karl-Günter Technau; Michael T Yin
Journal:  South Afr J HIV Med       Date:  2021-08-05       Impact factor: 2.744

4.  Persistently lower bone mass and bone turnover among South African children living with well controlled HIV.

Authors:  Yanhan Shen; Stephanie Shiau; Renate Strehlau; Megan Burke; Faeezah Patel; Cara T Johnson; Bridgette Rizkalla; Gallagher Dympna; Louise Kuhn; Ashraf Coovadia; Michael T Yin; Stephen M Arpadi
Journal:  AIDS       Date:  2021-11-01       Impact factor: 4.632

5.  Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy.

Authors:  F Guo; X Song; Y Li; W Guan; W Pan; W Yu; T Li; E Hsieh
Journal:  Osteoporos Int       Date:  2020-08-15       Impact factor: 5.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.